Acne drug which causes birth defects too hard to monitor

According to the birth watchdog group the March of Dimes, preventing birth defects from a widely used acne drug is too heavy a burden on doctors, patients and pharmacists.

Doctors say that the restrictions placed on Accutane and generic versions are so complex and time-consuming patients may well resort to the Internet, where counterfeit medicines may be accessed with little regard to safeguards to prevent pregnancy.

Accutane is a prescription medication used to treat severe acne that causes multiple inflamed cysts and scarring which has not responded to other treatments.

It is a member of a family of drugs called retinoids, which are related to vitamin A, and when taken during pregnancy, they can cause very serious birth defects or miscarriages.

At present Accutane is the only drug approved for the condition and several attempts have been made since its 1982 approval to prevent pregnancies among women taking the drug.

Before the drug was approved, testing had shown that it could cause fetal abnormalities in animals, and drug company Roche warned against its use by pregnant women, but pregnancies resulting in birth defects still occur.

According to the March of Dimes, more than 1,000 women have become pregnant while using Accutane.

Stricter measures on sales of the drug are due to take effect from March 1, but many dermatologists have already adhered to the restrictions.

Dr. Diane Thiboutot of the American Academy of Dermatology has apparently reported to the a U.S. Food and Drug Administration (FDA) advisory panel of the confusion and frustration experienced by pharmacists, doctors and patients and is seeking a delay of two months before the new program takes full effect.

The new plan means that patients, doctors, pharmacists and wholesalers must register with drug makers and must tell patients about risks.

Women of child-bearing age will be required to sign consent forms and undergo monthly pregnancy tests.

A computer system that verifies the safety steps have been followed, is hard to access via the Internet or phone.

According to Thiboutot, a computer system that verifies the safety steps have been followed is hard to access via the Internet or phone and passwords sent by mail, are often too late to get a prescription filled.

This can entail some patients in multiple visits to a doctor while seeking help by phone may mean a wait of several hours, she said.

Efforts are apparently being made by the company that runs the pregnancy prevention program, Covance Inc., to make the system easier to use.

Dr. Sandra Kweder, deputy director of the FDA Office of New Drugs, says they too are working with companies to fix problems and may delay the start date.

The March of Dimes says there is an extremely high risk of fetal malformations if a woman becomes pregnant while taking Accutane, even if she is taking a small amount of the drug for a short period.

Birth defects linked with Accutane include: hydrocephaly (enlargement of the fluid-filled spaces in the brain); microcephaly (small head); mental retardation; ear and eye abnormalities; cleft lip and palate and other facial abnormalities; and heart defects.

Accutane can cause these birth defects in the early weeks after conception when a woman often does not know she is pregnant.

Even babies without obvious malformations may have mental retardation or learning disabilities.

The drug also increases the risk of miscarriage, premature delivery and infant deaths.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study identifies potential epigenetic biomarker for preeclampsia